Poly(ethylene carbonate) (PEC) is a unique biomaterial showing significant potential for controlled drug delivery applications. The current study investigated the impact of the molecular weight on the biological performance of drug-loaded PEC films.
Introduction
Advances in the field of chemical engineering and the biomedical sciences have made polymer drug carriers available, which allow for modification of the delivery rate of the embedded therapeutic agent [1] . The drug release may occur constantly over an extended period of time, typically by means of polymer degradation and/or diffusion through the polymer matrix, with the aim of obtaining constant plasma levels, reducing side effects and prolonging dosing intervals [2] . Biodegradable polyesters such as poly (lactide-co-glycolide) have been most-frequently utilized as matrix materials for controlled drug delivery devices [3, 4] . However, the hydrolytic degradation behavior (i.e., bulk erosion [5] , formation of acidic microclimate within the drug carrier [6] ) often results in a rather uncontrolled drug release profile [7] and chemical instability for numerous therapeutic agents [8, 9] .
In contrast, polymers that degrade solely by surface erosion have demonstrated more predictable drug release kinetics [10] . Biodegradable poly(ethylene carbonate) (PEC) is a promising example of such a polymer [11] . Diverse PEC-based drug delivery vehicles have been shown to degrade from the surface in vitro and in vivo [11] [12] [13] , resulting in a favorable drug release profile [14, 15] . Furthermore, the degradation of PEC is triggered by specific enzymes and cells [16, 17] making this type of polymer especially attractive for on-demand drug release to desired sites within the body [18] . Despite the significant potential of PEC for controlled drug delivery applications, only scant information is available describing the biomedical performance (i.e., biodegradation and drug release) of drug delivery vehicles composed of PEC of different molecular weight [19] .
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In this respect, the current study aimed to close this gap by investigating the impact of the polymer molecular weight on the degradation of and drug release rate from surface-eroding PEC films in detail. Polymers and polymer films either loaded with rifampicin or fluorescently-labelled bovine serum albumin (BSA) were thoroughly characterized before studying their in vitro degradation and drug release behavior in the absence and presence of the enzyme cholesterol esterase. Degradation tests in cell culture (i.e., RAW264.7 macrophages) and in vivo (i.e., subcutaneous implantation in rats) underlined the unique potential of PEC for prolonged drug delivery applications.
Materials and methods

Materials
PEC, QPAC
Ò 25 was purchased from Empower Materials (USA).
PEC polymers of lower molecular weight were obtained by thermal hydrolysis in boiling water (Fig. S1 , Supplementary materials) [16, 17, 19] . Rifampicin (!97%), fluorescein isothiocyanate (FITC)-labeled BSA (!7 mol FITC/mol BSA) and cholesterol esterase (from porcine pancreas) were acquired from Sigma-Aldrich (UK). All other chemicals and solvents were of analytical grade and used without further purification.
Gel permeation chromatography (GPC)
Samples were dissolved in chloroform (3-4 mg/ml). After filtration (0.2 lm; Acrodisc Ò , Pall, Germany), 100 ll of the sample solution was injected into the system, consisting of two columns from Polymer Laboratories (PL-gel MIXED-D; 300 Â 7.5 mm; bead diameter 5 lm) and a differential refractive index detector (SpectraSystem RI-150, Thermo Electron Corp., USA). The elution was performed with chloroform at a flow rate of 1 ml/min and toluene as flow-rate marker. Poly(methyl methacrylate) standards of known molar masses were used for calibration.
Viscosity measurements
The viscosity of PEC samples dissolved in chloroform was measured using a capillary viscometer of the Ubbelohde Semi-Micro dilution type (No. 50, N213, CANNON Instrument Company, USA) at 25.0 ± 0.2°C. Values for the specific (g sp ) and intrinsic viscosity ([g]) were calculated using standard equations.
Differential scanning calorimetry (DSC)
The glass transition temperature (T g ) of polymers and polymer films was determined using a differential scanning calorimeter (Discovery DSC, TA Instruments, Denmark). Samples ($3-5 mg)
were scanned at a rate of 10°C/min from À40°C to 190°C under a nitrogen atmosphere.
X-ray powder diffraction (XRPD)
Wide-angle XRPD patterns were recorded on a X'Pert PROMPD X-ray diffractometer (PANalytical, The Netherlands). Samples were measured in Bragg Brentano reflection mode in the 2h range of 5-37°using a PIXel detector (step size of 0.039°). The X-ray source was Ni-filtered CuK a1 radiation (k = 1.541 Å). The operating current and voltage were 40 mA and 45 kV, respectively. The aluminum sample holder was spun throughout data collection to avoid orientation artifacts.
Scanning electron microscopy (SEM)
Samples were placed on double-sided carbon tape, mounted on stubs and sputter coated with a 5 nm layer of gold using a Leica EM ACE200 (Germany) prior to sample imaging. The images were acquired with an FEI/Philips XL30 FEG (USA) at an acceleration voltage of 2 kV using the secondary electron detector.
Preparation of polymer films
PEC films were fabricated by a solvent casting technique [20, 21] . Therefore, PEC without or with added rifampicin (10 wt. % per polymer mass) were accurately weighed and then dissolved in chloroform at a concentration of 100 mg/ml. For films loaded with BSA, PEC was first dissolved in chloroform (100 mg/ml) containing Span Ò 80 (1 mg/ml). BSA was dissolved in water (10 mg/ ml) in parallel before mixing the two solutions (ratio of 9/1 (v/v)) using a homogenizer (T25 Ultra-Turrax Ò , IKA, Germany). Film solutions (500 ll) were then transferred to custom-made Teflon Ò dishes (diameter: 10 mm, height: 3 mm) and the organic solvent was allowed to evaporate under a fume hood overnight. The films were then cut into discs, and dried under reduced pressure ($0.1 mbar).
Enzymatic polymer degradation
Polymer film samples ($25 mg) were transferred to 2 ml of phosphate-buffered saline (PBS, pH 7.4) without or with added cholesterol esterase (0.1 mg/ml). The films were incubated at 37°C with shaking (Rotatherm Ò , Gebr. Liebisch, Germany). The medium was exchanged every 3-4 d. At predetermined time points the incubation was terminated by removal of the supernatant. Polymer films were washed several times with distilled water and subsequently freeze-dried (Beta I, Christ, Germany) overnight. The remaining film mass and molecular weight was determined gravimetrically (BP 211 D, Sartorius, Germany) and by GPC as described above, respectively. The in vitro drug release studies were carried out in PBS without or with added cholesterol esterase (0.1 mg/ml) under sink conditions. $30 mg of rifampicin-loaded (drug loading of 10 wt.%) or BSA-loaded (drug loading of 1 wt.%) PEC films were incubated in the release medium while shaking at 37°C. The release medium was removed at each sampling time point and replaced with fresh medium before determining the cumulative drug release.
Rifampicin quantification
Rifampicin concentrations were assessed by reversed-phase high performance liquid chromatography on a Shimadzu system (Japan) using a Phenomenex Kinetex XB-C18 (50 mm Â 2.1 mm, 2.6 lm) column (Denmark) (flow rate of 0.5 ml/min). Samples were analyzed using a 5-15% (v/v) B gradient over 3. 
BSA quantification
BSA concentrations were determined by fluorescence spectroscopy (FLUOstar OPTIMA, BMG labtech, Germany) and the bicinchoninic acid protein assay reagent (Pierce, USA) before calculating the cumulative amount of BSA released. Fluorescence intensity (k ex = 460 nm and k em = 515 nm) was assayed in 96-well microplates.
Cell culture
Murine macrophages (RAW264.7) were acquired from ATCC (TIP-71, USA). Cells were maintained in Dulbecco's Modified Eagle's Medium supplemented with penicillin (100 U/ml), streptomycin (100 lg/ml), 2 mM L-glutamine (all from Sigma-Aldrich, UK) and 10% (v/v) of fetal bovine serum (PAA Laboratories, Austria) and cultured in an air atmosphere conditioned with 5% CO 2 at 37°C. The medium was changed three times per week and cells were split twice weekly (cell detachment by scraping). Cells were used between passages 5 and 12.
Cellular polymer degradation
PEC films ($50 mg) were disinfected with ethanol before transferring them into prefilled (50,000 macrophages per ml medium, 2.5 ml) 6-well cell culture plates. The culture plates were then incubated as outlined above. At predetermined time points, the incubation was stopped by removing the films from the well plates. The films were treated with 1 wt.% aqueous Triton X-100 detergent (Sigma-Aldrich, UK) for 60 min and then extensively rinsed with distilled water. After freeze-drying, the remaining film mass and molecular weight was determined as outlined above.
Polymer degradation in vivo
Male Sprague-Dawley rats ($250 g; Charles River, Denmark) were used for the in vivo evaluation of polymer degradation. Animals were allowed free access to water and food and were housed under controlled environmental conditions (constant temperature and humidity with a 12 h dark-light cycle).
The animals were anaesthetized by isoflurane/oxygen inhalation (Scanvet, Denmark) and kept with the mask during the entire surgical procedure. Buprenorphine (0.3 ml, 10% in isotonic saline) was administered subcutaneously preoperatively. For each rat, the skin was incised along the midline of the back and two pockets were prepared by dissecting the subcutaneous tissue on both right and left side of the incision. Into each pocket, one polymer film of 1 cm 2 (thickness of 1-2 mm) of predetermined molecular weight (around 60 mg in total) was placed followed by skin closure. Following 3, 7 and 10 d, animals were anaesthetized and the films were retrieved, cleaned and freeze-dried for weighing and molecular weight determination. Animals were finally euthanized by an overdose of sodium pentobarbital. All experiments and procedures described herein were in accordance with the National Institutes of Health guidelines on the care and use of laboratory animals. The study protocol was further approved by the Danish Animal Experiments Inspectorate (approval No. 2014-15-0201-00031).
Statistics
All experiments/measurements were carried out in triplicate and values are presented as the mean ± standard deviation (SD) unless otherwise stated. To identify statistically significant differences, an unpaired t-test analysis was performed. Probability values of p < 0.05 were considered significant.
Results and discussion
The medical field would clearly profit from polymer excipients allowing for a predictable drug release behavior. Further, it would be attractive to design drug delivery vehicles with certain specificity for cells and/or tissues and thus, an on-demand release in order to minimize systemic drug distribution [18] . This task is often difficult to achieve, especially when employing bulkeroding polymers such as poly(lactide-co-glycolide) [5, 7, 22] . In contrast, surface-eroding PEC carries significant potential to meet these specific requirements. However, as the speed of biodegradation dictates the release kinetics of the encapsulated therapeutic agent for drug delivery devices undergoing surface erosion, a deeper understanding of the influence of the molecular weight of the utilized PEC is therefore, considered important.
Characterization of polymers and drug-loaded polymer films
The physicochemical properties of the synthesized PEC are outlined in Table 1 . Polymers with different weight-average molecular weight (M w ) were prepared by thermal hydrolysis of commercially available PEC196 (Fig. S1, Supplementary materials) [16, 17, 19] with the aim to study the impact of M w on the biomedical performance of polymer films in detail. The M w of degraded polymer samples, assessed by means of GPC, ranged between 196 and 85 kDa. GPC analysis further indicated relatively broad dispersities (Ð) of degraded polymers (>2.0) [12] , which were, however, more narrowly distributed than the starting material (PEC196) (Figs. S1B and S2, Supplementary materials) . The approach of Ð towards 2 is an indication of random chain scission during the employed degradation process. Proton nuclear magnetic resonance spectroscopy confirmed the composition (>95% ethylene glycol) of the utilized polymers (data not shown).
The viscosity of the polymers dissolved in chloroform increased as a function of the polymer concentration and M w (Fig. S3 , Supplementary Materials).
[g] values ranged between 0.6 and 1.0 dl/g ( Table 1 ). The relationship of [g] and M w of PEC dissolved in chloroform is illustrated in Fig. S4 (Supplementary Materials) , which showed a linear correlation for the investigated polymers. Application of the Mark-Houwink equation for the specific polymersolvent system, gave a value of 0.032 dl/g and 0.66 for k and a, respectively. The exponent a is indicative of the PEC chain geometry in chloroform. A value of 0.5 indicates a h-solvent, while a value between 0.5 and 0.8 reflects a random polymer coil in a ''good" solvent.
DSC measurements of the distinct polymers showed minor differences in T g , with all polymers having a T g below room temperature ( Table 1 ). The T g of PEC85 (15°C) was the lowest, while that of PEC196 was the highest (17°C). Elevated T g values are typically seen when increasing the M w of amorphous and semi-crystalline polymers (Flory-Fox relationship) [23] . It was further observed, that rifampicin-loaded PEC films (10 wt.%) showed a higher T g compared to the polymers alone. Thus, rifampicin shifted the drug-polymer mixture toward higher T g , most-likely due to an anti-plasticizer effect of this drug [24, 25] . For all rifampicinloaded PEC films a single T g event was observed (data not shown), which is an indication of the drug being molecularly dispersed in the polymer matrix. In contrast, embedded BSA had no relevant influence on the T g of the investigated PEC films.
XRPD was performed for the PEC polymers and rifampicinloaded PEC films (10 wt.%) (Fig. 1 ). All polymers (Fig. 1A) and rifampicin-loaded polymer samples (Fig. 1B) were amorphous, while unprocessed rifampicin powder alone was (mainly) crystalline. This result supports the thermoanalytical measurements, where all samples showed no melting endotherm for rifampicin. BSA-loaded PEC films were also of amorphous nature (data not shown).
Polymer film degradation
Degradation studies of the PEC films were performed in the presence and absence of cholesterol esterase (Fig. 2) . This enzyme is expressed by several cells including macrophages [26] and pancreatic cells [27] and has been demonstrated to actively degrade PEC in vitro [16] . Polymer films showed clear signs of surface erosion in the presence of cholesterol esterase (no degradation in PBS without added cholesterol esterase). Interestingly, the degradation rate was shown to be dependent on the M w of the employed polymer ( Fig. 2A) . Faster degradation was observed for higher M w (PEC196, degradation half-life (t 1/2 ) of $9 d), whereas PEC85 revealed remarkably slower degradation rates (degradation t 1/2 of $14 d). Fig. 2B illustrates that the polymer M w remained constant throughout the degradation study under both incubation conditions. Thus, the length of individual polymer chains remained constant while the film samples experienced relevant mass loss, indicating erosion of a full-length polymer chain from the film. This behavior is strikingly different from what is typically reported for bulk-eroding polymers. As an example, poly(lactideco-glycolide) undergoes a mass loss and decrease in polymer M w once in contact with aqueous media [22] . Shorter polymer chains (lower M w ) generally tend to experience a quicker degradation process compared with longer polymer chains (higher M w ). One possible explanation for the observed degradation rates for PEC films of different M w could be attributed to differences in the individual polymer structure. As outlined by Acemoglu et al. [12] , the synthesis of PEC results in the formation of both -(O(CO) OCH 2 CH 2 )-and -(O(CO)(OCH 2 CH 2 ) x )-repeating units. Here, the -(O(CO)(OCH 2 CH 2 ) x )-units, which are thought to be selectively hydrolyzed during the aqueous thermal degradation process used to generate the lower M w specimens of PEC, are more hydrophilic. Thus, PEC196 is expected to be the most hydrophilic polymer of the series. Accordingly, the polymer degradation by cholesterol esterase (and the accompanied rapid drug release profiles) showed an ''inverse" dependency on M w . This hypothesis was challenged by incubating PEC196 and PEC85 with cholesterol esterase and comparing the morphology of the degraded films by means of SEM (Fig. 3) .
As expected, a rough surface with pore formation was visible for PEC196 films indicating a relieved degradation by cholesterol esterase of this polymer. In contrast, the surface of PEC85 films was rather ''smooth" over the time-course of incubation (only little difference was seen to freshly-prepared PEC films (Fig. S5, Supplementary materials) ). In this context, the polymer chain flexibility needs to be considered, where PEC196 is thought to relax (''healing" process of polymer surface) the slowest because of the higher M w [28] . Thus, the surface of PEC85 remained ''smoother" during enzyme degradation, due to less pronounced erosion and a higher rate for ''repair" of the surface (Fig. 4) .
Drug release
The release of a small, rather hydrophobic drug and a large, hydrophilic protein was studied from the diverse PEC films (Figs. 5-7 ). In the absence of cholesterol esterase, no burst release of rifampicin (<10%) was detected, indicating no relevant diffusional drug transport through the polymer matrix (Fig. 5A) . In contrast, a gradual rifampicin release from all investigated polymer films was obtained in the presence of cholesterol esterase, however, at substantial different release rates (Fig. 5B) . Here, PEC196 showed the fastest drug release rate followed by PEC174, PEC133, PEC110 and PEC85. PEC196 released $75% of its payload over 14 d, while PEC85 delivered only $40% of the encapsulated rifampicin content. The calculated t 1/2 values of PEC film degradation (Fig. 2) and rifampicin release curves (Fig. 5) in the presence of cholesterol esterase were plotted, where a linear correlation was obtained (Fig. 6) . The slope of the resulting line of regression was >1, which is indicative for a slightly faster rifampicin release compared to what one would expect by a drug release process mediated by ''simple" surface erosion.
In a second set of release experiments, the delivery of BSA was studied from PEC films in the absence and presence of cholesterol esterase (Fig. 7) . Without added cholesterol esterase, PEC196 experienced a considerably higher BSA release ($30-40%) compared to PEC85 (<10%) (Fig. 7A ). When incubated with cholesterol esterase, a progressive BSA release was seen from the investigated PEC196 and PEC85 films, again at substantial different release rates (Fig. 7B) . PEC196 delivered the complete BSA payload within the incubation period. In contrast, PEC85 showed a slower BSA release profile with $60% of the encapsulated amount delivered after 14 d. As discussed above (Figs. 2 and 3) , this elevated BSA release rate observed for PEC196 is likely attributed to the difference in polymer degradation by cholesterol esterase, leading to a distinct drug release profile [15, 16, 19] .
Overall, the release of rifampicin and BSA from PEC films of different M w matched the observations made during the film degradation study, where the highest polymer erosion rate was seen for the PEC with the highest M w (i.e., PEC196). Thus, the M wdependent erosion of PEC could be used to tailor a desired release profile for both rather small drugs and biomacromolecules. Here, especially rifampicin revealed remarkably linear (predictable) release kinetics. It was further demonstrated in vitro, that the drug delivery from PEC was initiated by an enzyme-specific surface erosion process of the delivery vehicle, which can be considered as a prerequisite for an on-demand drug delivery to a desired cell population or tissue/organ within the body. Although the release curves of BSA from PEC films resemble what one would expect by diffusion through an interconnecting pore network, bulkeroding polymers, such as conventional polyesters, share none of the above mentioned auspicious degradation and drug release features [5, 22, 29] . Thus, further work should focus on the influence of the morphology of the drug delivery device (e.g., pore network under degradation) on the resulting drug release profile. 
Polymer film degradation by macrophages and in vivo
Degradation studies in cell culture and in vivo underlined the unique potential of PEC as biomaterial for prolonged drug delivery applications (Figs. 8-11 ). Polymer films, which were incubated with RAW264.7 macrophages, showed rapid mass loss as a function of the employed M w with degradation t 1/2 of $3 and $5 d for PEC196 and PEC85, respectively (Fig. 8A) . During the incubation process, no relevant change of polymer M w was detected (Fig. 8B) . No degradation occurred in plain cell culture medium (i.e., no mass loss, change of polymer M w or film surface (data not shown)), while the morphology of the freshly-prepared PEC films (Fig. S5 , Supplementary materials) changed dramatically when incubated with macrophages (Fig. 9) . As it can be seen from the SEM images, the surface of degraded PEC196 and PEC85 films revealed obvious difference with respect to the porous microstructure. PEC196 films showed mainly numerous small pores (with a cross-section <10 lm) as well as large holes (cross section >200 lm), where the macrophages had fully penetrated the polymer film. In contrast, degraded PEC85 films were characterized by an overall lower number of pores. Besides bigger holes, which matched the size of RAW264.7 macrophages (10-20 lm in diameter), also smaller pores below the size of the cells were visible. These findings further indicated that the polymer structure of PEC196 films was easier to penetrate for the RAW264.7 macrophage cell line. Thus, the process by which the polymer films were degraded by RAW264.7 macrophages (i.e., surface erosion) was in general agreement with the observations from the studies with cholesterol esterase (Figs. 2 and 3) . However, the overall rate of PEC degradation was more pronounced in cell culture (Fig. 8) . One possible explanation for the distinct extent of surface erosion could be the higher local concentration of distinct degrading enzymes (and/or radicals) of RAW264.7 macrophages, which are found in close proximity to the polymer film, compared to ''simple" cholesterol esterase solution.
Degradation studies of polymer films were also performed after subcutaneous implantation in rats (Figs. 10 and 11 ). PEC196 and PEC85 films were rapidly eroded in vivo (Fig. 10A) , with no significant change of M w over the time-course of implantation (Fig. 10B) . The mechanism (i.e., surface erosion) and overall rate of polymer degradation in vivo were similar to the studies conducted with cholesterol esterase (Fig. 2) and RAW264.7 macrophages (Fig. 8) . When comparing the time-course of PEC196 and PEC85 film morphology during in vivo degradation (Fig. 11) , the surface structure of PEC196 and PEC85 and thus, the specific surface erosion mechanism by which the two tested polymers were degraded, was strikingly different. As seen for cholesterol esterase-mediated (Fig. 3) and RAW264.7 macrophage-mediated (Fig. 9) polymer film degradation, numerous pores were formed on the surface of PEC196, which then transformed to a "rough" polymer interface with time.
In contrast, the surface of PEC85 films was rather ''smooth", characterized by less, but larger scoop-like pores, which underwent significant progression during the time-course of in vivo degradation. Previous studies have reported that the biodegradation of PEC in vivo was mainly triggered by immuno-competent cells, which rapidly attached to the polymer surface after implantation [11, 14] . Released enzymes (and/or radicals) then initiated the surface degradation process. Here, a close proximity of macrophages to the PEC surface was considered essential [14] . However, these general findings cannot explain the observed discrepancy of surface morphology for PEC196 and PEC85 films during in vitro and in vivo degradation and its general implication on an accompanied drug release process. Besides the faster rate of surface erosion observed for PEC196, the formation of many "small" pores and a "rough" film surface during biodegradation (increase in surface area) would cause an even faster, surface erosion-controlled drug release, an issue that clearly deserves further clarification/ investigations.
Conclusions
A biomaterial with potential for an on-demand drug release would add significant benefit to the biomedical field. Controlled drug delivery vehicles, which could defer drug release until Fig. 11 . SEM images of the time-course of PEC196 and PEC85 film degradation after implantation in rats. Scale bars = 100 lm.
reaching a certain target and/or are ''activated" by specific stimuli (e.g., enzymes or cells) would limit systemic drug exposure and drug dose, and consequently reduce side effects. Among the large number of natural and synthetic polymers, PEC is one of such promising biomaterials, which undergoes enzyme-and cellspecific surface erosion in vitro and in vivo. Consequently, delivery systems made from PEC result in predictable drug release patterns. In this respect, the current study identified the molecular weight of PEC as an essential parameter to control the spatial and temporal drug release from the employed delivery system. Overall, surface-eroding PEC is thought to result in a suitable on-demand drug release to the desired site of action avoiding high and uncontrollable systemic drug levels.
